Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IEC 2021 | GABAergic signaling in autism spectrum disorders

James Clement • 20 Aug 2021
IEC 2021
General

James Clement, PhD, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore, India, discusses the role of GABAergic signaling in autism spectrum disorders. Studies from autistic mouse models and patients have suggested that γ-Aminobutyric acid (GABA) is one of the major therapeutic targets for autism spectrum disorders due to GABAergic neuron functions being affected as a result of mutations in genes involved with autism. Dr Clement talks on the activation and inhibitory effects of GABA and the outcomes of disrupting the GABAergic signaling pathway. This interview took place during the 34th International Epilepsy Congress, 2021.

More from James Clement

0:46
The next steps in autism treatment: gene therapy
James Clement • 20 Aug 2021
1:45
Upcoming clinical trials for small molecules to treat autism spectrum disorder
James Clement • 20 Aug 2021
0:49
GABA suppressing drugs in epilepsy treatment
James Clement • 20 Aug 2021

Related Videos

2:51
RECOVER-NEURO: testing cognitive function interventions for long-COVID
Leigh Charvet • 23 Feb 2024
4:17
AI in neurology: considering the push and pull factors
Sanjay Budhdeo • 22 Mar 2024
2:59
New initiatives from NeuroNEXT: clinical trial support for academic and industry partners
Aleksandar Videnovic • 15 Apr 2024
1:17
Growing evidence for sleep and brain health
Karin Johnson • 14 Apr 2024
The content of VJNeurology is intended for healthcare professionals